Search research articles
Contact Us
Filters
Showing results (361-370 of 373) with videos related to
Page
of 38
Sort By:
Plos One
|
February 4, 2014
Body mass index and breast cancer defined by biological receptor status in pre-menopausal and post-menopausal women: a multicenter study in China
Jing Li, Yuan Huang, Bao-Ning Zhang, et al.
Clinical Breast Cancer
|
October 30, 2012
Epidemiologic study of radiotherapy use in China in patients with breast cancer between 1999 and 2008
Shu-Lian Wang, Ye-Xiong Li, Bao-Ning Zhang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
August 1, 2006
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors]
Pin Zhang, Feng-yi Feng, Ling-ying Wu, et al.
Nature Medicine
|
November 5, 2021
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Binghe Xu, Qingyuan Zhang, Pin Zhang, et al.
Chinese Medical Journal
|
January 17, 2025
Five-year outcomes of metabolic surgery in Chinese subjects with type 2 diabetes
Yuqian Bao, Hui Liang, Pin Zhang, et al.
Chinese Medical Journal
|
April 26, 2022
Clinical practice guideline for body composition assessment based on upper abdominal magnetic resonance images annotated using artificial intelligence
Han Lv, Mengyi Li, Zhenchang Wang, et al.
BMJ Open
|
September 29, 2022
Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for type 2 diabetes remission (ORDER): protocol of a multicentre, randomised controlled, open-label, superiority trial
Mengyi Li, Yang Liu, Wei-Jei Lee, et al.
The Lancet. Oncology
|
May 14, 2023
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Pin Zhang, Qingyuan Zhang, Zhongsheng Tong, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
April 3, 2004
[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer]
Zhong-zhen Guan, Dong-geng Liu, Bao-ming Yu, et al.
Annals of Translational Medicine
|
November 26, 2015
National consensus in China on diagnosis and treatment of patients with advanced breast cancer
Binghe Xu, Xichun Hu, Zefei Jiang, et al.
Page
of 38
Search research articles
Search
Showing results (361-370 of 373) with videos related to
Sort By:
Page
of 38
Plos One
|
February 4, 2014
Body mass index and breast cancer defined by biological receptor status in pre-menopausal and post-menopausal women: a multicenter study in China
Jing Li, Yuan Huang, Bao-Ning Zhang, et al.
Clinical Breast Cancer
|
October 30, 2012
Epidemiologic study of radiotherapy use in China in patients with breast cancer between 1999 and 2008
Shu-Lian Wang, Ye-Xiong Li, Bao-Ning Zhang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
August 1, 2006
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors]
Pin Zhang, Feng-yi Feng, Ling-ying Wu, et al.
Nature Medicine
|
November 5, 2021
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Binghe Xu, Qingyuan Zhang, Pin Zhang, et al.
Chinese Medical Journal
|
January 17, 2025
Five-year outcomes of metabolic surgery in Chinese subjects with type 2 diabetes
Yuqian Bao, Hui Liang, Pin Zhang, et al.
Chinese Medical Journal
|
April 26, 2022
Clinical practice guideline for body composition assessment based on upper abdominal magnetic resonance images annotated using artificial intelligence
Han Lv, Mengyi Li, Zhenchang Wang, et al.
BMJ Open
|
September 29, 2022
Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for type 2 diabetes remission (ORDER): protocol of a multicentre, randomised controlled, open-label, superiority trial
Mengyi Li, Yang Liu, Wei-Jei Lee, et al.
The Lancet. Oncology
|
May 14, 2023
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Pin Zhang, Qingyuan Zhang, Zhongsheng Tong, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
April 3, 2004
[First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer]
Zhong-zhen Guan, Dong-geng Liu, Bao-ming Yu, et al.
Annals of Translational Medicine
|
November 26, 2015
National consensus in China on diagnosis and treatment of patients with advanced breast cancer
Binghe Xu, Xichun Hu, Zefei Jiang, et al.
Page
of 38